111 related articles for article (PubMed ID: 12500209)
1. Treatment of transfusion-dependent thalassemic patients infected with hepatitis C virus with interferon alpha-2b and ribavirin.
Sherker AH; Senosier M; Kermack D
Hepatology; 2003 Jan; 37(1):223. PubMed ID: 12500209
[No Abstract] [Full Text] [Related]
2. A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration.
Huang CF; Dai CY; Huang JF; Chuang WL; Yu ML
Hepatology; 2009 Apr; 49(4):1395-6; author reply 1396. PubMed ID: 19330867
[No Abstract] [Full Text] [Related]
3. Shortened therapy for hepatitis C virus genotype 2 or 3--is less more?
Liang TJ
N Engl J Med; 2007 Jul; 357(2):176-8. PubMed ID: 17625131
[No Abstract] [Full Text] [Related]
4. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin.
Fried MW; Peter J; Hoots K; Gaglio PJ; Talbut D; Davis PC; Key NS; White GC; Lindblad L; Rickles FR; Abshire TC
Hepatology; 2002 Oct; 36(4 Pt 1):967-72. PubMed ID: 12297845
[TBL] [Abstract][Full Text] [Related]
5. [High dosage induction brings new hope].
MMW Fortschr Med; 2005 Dec; 147(51-52):68. PubMed ID: 16404784
[No Abstract] [Full Text] [Related]
6. Shorter treatment for hepatitis C genotype 4 may be a possibility.
Iqbal S; Mansour M; Cerulli MA
South Med J; 2008 Jan; 101(1):106. PubMed ID: 18176306
[No Abstract] [Full Text] [Related]
7. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients.
Mukherjee S; Lyden E; McCashland TM; Schafer DF
J Gastroenterol Hepatol; 2005 Feb; 20(2):198-203. PubMed ID: 15683421
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin.
Legrand-Abravanel F; Sandres-Sauné K; Barange K; Alric L; Moreau J; Desmorat P; Vinel JP; Izopet J
J Infect Dis; 2004 Apr; 189(8):1397-400. PubMed ID: 15073676
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon alfa-2b and ribavirin in thalassaemia/chronic hepatitis C virus-co-infected non-responder to standard interferon-based.
Hamidah A; Thambidorai CR; Jamal R
Med J Malaysia; 2005 Oct; 60(4):517-9. PubMed ID: 16570722
[TBL] [Abstract][Full Text] [Related]
10. Remission of hepatitis C virus-associated cryoglobulinemic glomerulonephritis with interferon alfa-2b and ribavirin combination therapy after liver transplantation.
Sikaneta T; Williams WW; Chung RT; Cosimi AB; Pascual AM
Transplantation; 2002 Dec; 74(12):1767-8. PubMed ID: 12499895
[No Abstract] [Full Text] [Related]
11. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection.
Hung CH; Lee CM; Lu SN; Wang JH; Tung HD; Chen CH; Changchien CS
J Gastroenterol Hepatol; 2005 May; 20(5):727-32. PubMed ID: 15853986
[TBL] [Abstract][Full Text] [Related]
12. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases.
Buti M; Valdés A; Sánchez-Avila F; Esteban R; Lurie Y
Hepatology; 2003 May; 37(5):1226-7. PubMed ID: 12717407
[No Abstract] [Full Text] [Related]
13. [Epidemiological and clinical study for hepatitis C virus infection].
Hayashi J; Furusyo N
Fukuoka Igaku Zasshi; 2010 Mar; 101(3):46-52. PubMed ID: 20653197
[No Abstract] [Full Text] [Related]
14. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
[TBL] [Abstract][Full Text] [Related]
15. Current management of hepatitis C in New Zealand.
Gane E
N Z Med J; 2001 Mar; 114(1128):101-2. PubMed ID: 11346152
[No Abstract] [Full Text] [Related]
16. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
Andriulli A; Mangia A
N Engl J Med; 2007 Oct; 357(16):1660; author reply 1661-2. PubMed ID: 17942881
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
Henry MJ
N Engl J Med; 2005 Sep; 353(11):1182-3; author reply 1182-3. PubMed ID: 16167381
[No Abstract] [Full Text] [Related]
19. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
Liu CH; Chen DS; Kao JH
N Engl J Med; 2007 Oct; 357(16):1661; author reply 1661-2. PubMed ID: 17948345
[No Abstract] [Full Text] [Related]
20. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.
Poynard T; Ratziu V; McHutchison J; Manns M; Goodman Z; Zeuzem S; Younossi Z; Albrecht J
Hepatology; 2003 Jul; 38(1):75-85. PubMed ID: 12829989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
